254 related articles for article (PubMed ID: 28074067)
1. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.
Schütz C; Inselmann S; Saussele S; Dietz CT; Mu Ller MC; Eigendorff E; Brendel CA; Metzelder SK; Bru Mmendorf TH; Waller C; Dengler J; Goebeler ME; Herbst R; Freunek G; Hanzel S; Illmer T; Wang Y; Lange T; Finkernagel F; Hehlmann R; Huber M; Neubauer A; Hochhaus A; Guilhot J; Xavier Mahon F; Pfirrmann M; Burchert A
Leukemia; 2017 Apr; 31(4):829-836. PubMed ID: 28074067
[TBL] [Abstract][Full Text] [Related]
2. Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia.
Inselmann S; Wang Y; Saussele S; Fritz L; Schütz C; Huber M; Liebler S; Ernst T; Cai D; Botschek S; Brendel C; Calogero RA; Pavlinic D; Benes V; Liu ET; Neubauer A; Hochhaus A; Burchert A
Cancer Res; 2018 Nov; 78(21):6223-6234. PubMed ID: 30166420
[TBL] [Abstract][Full Text] [Related]
3. Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial.
Rinaldetti S; Pfirrmann M; Manz K; Guilhot J; Dietz C; Panagiotidis P; Spiess B; Seifarth W; Fabarius A; Müller M; Pagoni M; Dimou M; Dengler J; Waller CF; Brümmendorf TH; Herbst R; Burchert A; Janβen C; Goebeler ME; Jost PJ; Hanzel S; Schafhausen P; Prange-Krex G; Illmer T; Janzen V; Klausmann M; Eckert R; Büschel G; Kiani A; Hofmann WK; Mahon FX; Saussele S
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):266-271. PubMed ID: 29510895
[TBL] [Abstract][Full Text] [Related]
4. Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy.
Söderlund S; Persson I; Ilander M; Guilhot J; Hjorth-Hansen H; Koskenvesa P; Richter J; Saussele S; Mustjoki S; Olsson-Strömberg U
Leuk Res; 2020 Mar; 90():106310. PubMed ID: 32058176
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of monocyte-derived dendritic cells, T regulatory and Th17 cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Hus I; Tabarkiewicz J; Lewandowska M; Wasiak M; Wdowiak P; Kusz M; Legieć M; Dmoszyńska A; Roliński J
Folia Histochem Cytobiol; 2011; 49(1):153-60. PubMed ID: 21526503
[TBL] [Abstract][Full Text] [Related]
6. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
Legros L; Nicolini FE; Etienne G; Rousselot P; Rea D; Giraudier S; Guerci-Bresler A; Huguet F; Gardembas M; Escoffre M; Ianotto JC; Noël MP; Varet BR; Pagliardini T; Touitou I; Morisset S; Mahon FX;
Cancer; 2017 Nov; 123(22):4403-4410. PubMed ID: 28743166
[TBL] [Abstract][Full Text] [Related]
7. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
[TBL] [Abstract][Full Text] [Related]
8. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.
Irani YD; Hughes A; Clarson J; Kok CH; Shanmuganathan N; White DL; Yeung DT; Ross DM; Hughes TP; Yong ASM
Br J Haematol; 2020 Nov; 191(3):433-441. PubMed ID: 32352166
[TBL] [Abstract][Full Text] [Related]
10. Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
Kong J; Qin YZ; Zhao XS; Hou Y; Liu KY; Huang XJ; Jiang H
Ann Hematol; 2021 Oct; 100(10):2557-2566. PubMed ID: 34278524
[TBL] [Abstract][Full Text] [Related]
11. Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia.
Irani YD; Kok CH; Clarson J; Shanmuganathan N; Branford S; Yeung DT; Ross DM; Hughes TP; Yong ASM
Blood Adv; 2023 Jun; 7(11):2364-2374. PubMed ID: 36622326
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
[TBL] [Abstract][Full Text] [Related]
13. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
Caldemeyer L; Akard LP
Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
Iino M; Yamamoto T; Sakamoto Y
Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).
Fujisawa S; Ueda Y; Usuki K; Kobayashi H; Kondo E; Doki N; Nakao T; Kanda Y; Kosugi N; Kosugi H; Kumagai T; Harada H; Shikami M; Maeda Y; Sakura T; Inokuchi K; Saito A; Nawa Y; Ogasawara M; Nishida J; Kondo T; Yoshida C; Kuroda H; Tabe Y; Maeda Y; Imajo K; Kojima K; Morita S; Komukai S; Kawaguchi A; Sakamoto J; Kimura S
Int J Clin Oncol; 2019 Apr; 24(4):445-453. PubMed ID: 30421023
[TBL] [Abstract][Full Text] [Related]
16. [Tyrosine kinase inhibitor therapy discontinuation for chronic myelogenous leukemia to achieve clinical cure: current status and future perspectives].
Kumagai T
Rinsho Ketsueki; 2018; 59(10):2094-2103. PubMed ID: 30305514
[TBL] [Abstract][Full Text] [Related]
17. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
Bhalla S; Tremblay D; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia.
Shima H; Kada A; Tanizawa A; Sato I; Tono C; Ito M; Yuza Y; Watanabe A; Kamibeppu K; Uryu H; Koh K; Imai C; Yoshida N; Koga Y; Fujita N; Saito AM; Adachi S; Ishii E; Shimada H
Pediatr Blood Cancer; 2022 Aug; 69(8):e29699. PubMed ID: 35403816
[TBL] [Abstract][Full Text] [Related]
19. NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia.
Shah NP
J Natl Compr Canc Netw; 2019 May; 17(5.5):611-613. PubMed ID: 31117031
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
